BSAC Spring Conference 2020

Into Clinical Practice
- Bridging the gap between science, policy and effective antimicrobial use

A global overview of drug development and effective use through diagnostics, stewardship and shared learning

16-17 March 2020

Queen Elizabeth Conference Centre, Westminster, London

Professor David W. Denning

Infectious Diseases Clinician, Manchester

Dr Denning is an infectious diseases clinician with expertise in fungal diseases. He graduated from Guys Hospital in 1980 and trained in general medicine, paediatrics, microbiology and infectious diseases in London, Glasgow and Stanford, California. He was appointed as a Senior Lecturer and honorary Consultant in Infectious Diseases in Manchester in 1990, and promoted to Professor in 2005. He serves as the Chief Executive of the Global Action Fund for Fungal infections (GAFFI) and Professor of Infectious Diseases and Global Health at the University of Manchester, UK. Dr Denning manages the National Aspergillosis Centre, Manchester, a referral centre in the UK for all patients with chronic pulmonary aspergillosis. His current academic interests are chronic and allergic pulmonary fungal disease, the global burden of fungal infection, resistance in Aspergillus and getting new antifungals developed. He has published extensively (>600 academic papers) and has a citation H-index of 116. He leads LIFE (Leading International Fungal Education (www.LIFE-Worldwide.org), which is focused on improving patient outcomes through online education. He is the Chief Executive of the Global Action Fund for Fungal Infections (www.GAFFI.org), based in Switzerland and the UK which advocates for access to fungal diagnostics and antifungal therapies. He is the founder of 2 biotechnology companies – F2G Ltd (antifungal drug discovery and development in phase 2) and Myconostica Ltd (now Lab21) for molecular diagnostic tests for fungi.

Top